Lygos Appoints Bryce Dille as Vice President of Finance

Dille brings nearly 20 years of corporate finance, investment banking and capital markets experience. He has a strong track record in financing, having secured more than $500 million in both equity and debt financing before joining Lygos. He previously held senior financial positions at emerging public and private biotechnology companies, including Omada Health and TerraVia (formerly Solazyme), which was acquired by Corbion. Earlier in his career, Dille was a portfolio manager at Savitr Capital and Vice President and Senior Analyst for Clean Technology and Renewables at JMP Securities. He earned a Bachelor of Arts in Chemistry from Carleton College and is a Chartered Financial Analyst.

“Bryce has extensive experience in both the private and public capital markets, as well as a keen understanding of biotechnology business and finances,” said Eric Steen, PhD, CEO of Lygos. “As Lygos grows its programs and technology platform reach, I’m excited to have Bryce join us on our quest to replace toxic petrochemicals, reclaim local manufacturing and revive industrial chemical innovation.”

“Lygos has a solid foundation in place with an experienced management team, innovative technology platform and multiple strategic partnerships that can transform the production process for many large-scale industries,” said Dille. “I’m honored to join this team at this pivotal time as we look to accelerate our activities to meet the growing demand around the world for our sustainable, cost-competitive bio-based solutions.”

Lygos’ proprietary technology platform is based on a high-throughput combination of computational modeling, unique microbe engineering and screening, and machine learning. It is used to identify and develop new bio-routes to chemical functionalities that can expand the performance window in diverse materials systems. The company applies modern biotechnology to deliver the benefits of petroleum-based and other industrial chemical technologies without environmental toxicity at competitive prices. Lygos’ customers seek sustainable cost-efficient solutions for applications where industrial chemistry uses expensive, environmentally degrading options or has none to offer.

About Lygos
Lygos has created a full-stack biological engineering platform focused on organic acid specialty chemicals and bio-monomers. Lygos’ sustainable, bio-based chemicals replace expensive, environmentally degrading alternatives from traditional industrial suppliers, enabling customers to create better, safer products with value-added performance. For more information, visit www.lygos.com and follow us @LygosBiotech.

Lygos, the Lygos logo and Bio-Malonic are trademarks of Lygos, Inc. All other brands may be trademarks of their respective holders.

View source version on businesswire.com: https://www.businesswire.com/news/home/20190416005208/en/